On January 22, 2018 VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, reported that Shawn Singh, Chief Executive Officer of VistaGen, will provide an update on the Company’s Phase 2 study of AV-101 as an oral new generation adjunctive treatment for Major Depressive Disorder (MDD) and outline key 2018 initiatives at the 14th Annual Noble Capital Markets’ Investor Conference – NobleCon14 – to be held at the W Fort Lauderdale hotel in Fort Lauderdale, FL on Monday, January 29th at 4:30 p.m. ET (Press release, VistaGen Therapeutics, JAN 22, 2018, View Sourcenews/detail/80/vistagen-therapeutics-to-provide-update-on-phase-2-study-for-major-depressive-disorder-and-outline-key-2018-initiatives-at-the-14th-annual-noble-capital-markets-investor-conference" target="_blank" title="View Sourcenews/detail/80/vistagen-therapeutics-to-provide-update-on-phase-2-study-for-major-depressive-disorder-and-outline-key-2018-initiatives-at-the-14th-annual-noble-capital-markets-investor-conference" rel="nofollow">View Source [SID1234523421]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will be available via video webcast on VistaGen’s investor relations website, View Source, the day following the live presentation.

For more information about NobleCon14, or to schedule a one-on-one meeting with VistaGen’s management, please contact your Noble Capital Markets representative directly, or visit the conference website here.